Pricing Log in Create free account
Friday 6 November 2026 Export GILD’s income statement to Excel — free account

Gilead Sciences, Inc.

GILD Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.

Revenue
+6.83%
EPS
−20.3%
Free cash flow
+21.1%
Total debt
+5.17%

Quarter to September 2026, against a year earlier

167.46 7.02 −4.02%
Market cap
$207.8B
P/E
0.0×
Fwd P/E
−41.3×
Dividend yield
1.94%
F-score
8/9
Altman Z
4.03
Beneish M
−2.45
Dividend safety
77/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Gilead Sciences, Inc. (GILD) valuation and DCF model

What the price implies · reverse DCF

At $167.46 the price implies free cash flow after share-based pay growing 4.1% a year for ten years.

Free cash flow after share-based pay grew −7.4% a year over the last ten years, 1.4% over the last five. The price asks for 11.5 points a year more than its ten-year rate. The industry’s median company is priced for 11.2%.

In December 2017 the price assumed −6.4% a year; Gilead Sciences, Inc. went on to grow free cash flow after share-based pay −2.7% a year to FY2025.

Price implies
4.1%
Last 5 years, reported
1.4%
Last 10 years, reported
−7.4%
Industry median implies
11.2%

The headline discounts the last twelve months’ free cash flow after share-based pay at 9.0% for ten years and grows it 2.5% a year after that, the same for every company, so the figure compares across the market (how a reverse DCF works).

The other way round · DCF
The price needs
4.1% a year for ten years
$167.46
today’s price
Its base case
−7.4% a year for five years, then −4.4%
$69.31
58.6% below today’s price

Both are growth in free cash flow after share-based pay, discounted at 9.0%, with 2.5% a year after year ten.

Base case on its own ten-year record Gilead Sciences, Inc.’s own growth, carried forward

Its assumptions

Powerpack lets you start from a scenario and type over any of them.

The base case’s inputs, which Powerpack lets you change
1 · Cash flow to equity
the four quarters to September 2026, from the 10-Q and 10-K filings, before share-based pay

Yearly growth in cash flow. It usually slows as the company matures.

Today’s price implies free cash flow after share-based pay growing 4.1% a year for ten years.

2 · Rates

Cost of equity is the yearly return shareholders require, typically 8–11%. Terminal growth is growth forever after year 10, usually near long-run inflation, 2–3%.

3 · Per share

Diluted shares outstanding. Net debt, under Advanced inputs, is taken off before dividing.

Advanced inputs
Free cash flow Revenue and margin
negative is net cash
new shares the cash flow does not pay for

Against Gilead Sciences, Inc.’s own cost of capital: risk-free 4.3% + beta 0.37 × equity premium 4.5% = 6.0% cost of equity; weighted, 6.0%.

Use 6.0%
Equity value $86.69b ▼ below market cap $209.45b
Base case value per share $69.31 equity value ÷ 1.25b shares
Current price $167.46 market price per share
Below today’s price 58.6% downside at the base case’s assumptions

How we got there$60.00b 10 years of cash to equity+$46.48b terminal value−$19.79b net debt=$86.69b equity value÷1.25b shares=$69.31 per share

Valuation against its own history

Today’s multiple against its 5- and 10-year averages and the industry median (Drug Manufacturers General).

Multiple Current 5Y avg 10Y avg vs 10Y avg Industry median vs industry 10Y range
P/E — 63.45× 95.83× — 26.57× —
P/FCF 15.09× 13.85× 11.68× 29% above 21.34× 29% below
P/B 16.06× 7.68× 5.89× 173% above 5.20× 209% above
EV/EBITDA 505.05× 114.71× 63.05× 701% above 14.80× 3312% above
EV/Sales 7.35× 5.38× 4.64× 59% above 4.09× 80% above
P/E P/FCF P/B EV/EBITDA EV/Sales
12.10×183.42×354.75×526.07×10Y avg 95.83×2016201720182019202020212022202320242025

P/E has no reading today; its 10-year average is 95.83×.

Every growth rate on this page is the business’s — its cash flow, FFO or dividend — never its share price’s. A discounted-cash-flow model is only as good as its assumptions. Figures from the 10-K and 10-Q filings. Not investment advice.